NANOFÁRMACOS

Volver

Resultados 199 resultados LastUpdate Última actualización 14/10/2019 [16:12:00] pdf PDF xls XLS




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 8 nextPage   Mostrar por página


NANOPARTICLES IN WHICH ANTIGEN PEPTIDE AND ADJUVANT ARE BOUND TO FERRITIN SELF ASSEMBLY, AND USE THEREOF

NºPublicación: WO2019194393A1 10/10/2019

Solicitante:
IAC IN NAT UNIV CHUNGNAM [KR]

Resumen de: WO2019194393A1

The present invention relates to ferritin nanoparticles to which an antigen peptide and an adjuvant are bound. Since an antigen peptide or an adjuvant are indirectly bound to a ferritin self assembly by using HTTcys and VL12.3cys peptides, a fusion protein can be produced more easily than when an antigen and an adjuvant are directly fused, and also, the relative mole ratio of the antigen and the adjuvant can be readily adjusted, and thus the present invention can be effectively used as a vaccine composition.



traducir


 

BLOCK COPOLYMERS AND SELF-ASSEMBLING NANOPARTICLES FORMED THEREFROM

NºPublicación: US2019307684A1 10/10/2019

Solicitante:
IBM [US]
INST OF BIOENGINEERING AND NANOTECHNOLOGY BIOMEDICAL SCIENCES INST [SG]

Resumen de: US2019307684A1

The subject matter of this invention relates to block copolymers (BCPs) and, more particularly, to block copolymers capable of self-assembly into nanoparticles for the delivery of hydrophobic cargos. The BCPs include a hydrophobic block that contains a thioether functional group that is susceptible to oxidation, transforming the solubility of the block from hydrophobic to hydrophilic, thereby releasing the hydrophobic cargo of the nanoparticle.



traducir


 

CELLULOSE POWDER

NºPublicación: WO2019194085A1 10/10/2019

Solicitante:
ASAHI CHEMICAL IND [JP]

Resumen de: WO2019194085A1

The present invention provides a cellulose composite and a production method therefor, in which the cellulose composite comprises cellulose and a polysaccharide, and is characterized by the Bragg spacing of a precipitate obtained by centrifuging a 0.1 mass% aqueous dispersion of the cellulose composite being 8.6 nm or more according to small-angle X-ray scattering (SAXS) analysis.



traducir


 

NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE

NºPublicación: US2019307896A1 10/10/2019

Solicitante:
CLEVELAND CLINIC FOUND [US]

Resumen de: US2019307896A1

Provided herein are compositions, systems, kits, and methods for treating cancer in at least one bone of a subject using nanoparticles encapsulating, or conjugated to, an anti-cancer agent. In other embodiments, provided herein are composition, systems, kits, and methods for treating a bone disease (e.g., osteoporosis) in a subject using nanoparticle encapsulating, or conjugated to, a RANKL inhibitor. The nanoparticle are, in certain embodiments, neutral or nearly neutral in charge (e.g., zeta potential between −5 and +5 mV) and less than 250 nm in diameter on average (e.g. have an average diameter between 100 and 200 nm).



traducir


 

METHODS OF TREATING MITOCHONDRIAL AND METABOLIC DISORDERS

NºPublicación: US2019307732A1 10/10/2019

Solicitante:
ABRAXIS BIOSCIENCE LLC [US]

Resumen de: US2019307732A1

The present invention relates to methods and compositions for the treatment of diseases, such as mitochondrial-associated disorders, for example Leigh, MELAS, and NARP syndrome, and metabolic disorders, comprising administering an allosteric mTOR inhibitor, such as a composition comprising nanoparticles comprising an allosteric mTOR inhibitor and an albumin. Also provided are medicine and kits useful for the methods described herein.



traducir


 

PVP Coated Tellurium Nanorods with Antibacterial and Anticancer Properties

NºPublicación: US2019307895A1 10/10/2019

Solicitante:
UNIV NORTHEASTERN [US]

Resumen de: US2019307895A1

A nanoparticle formulation of tellurium nanorods. The tellurium nanoparticles are prepared using polyvinylpyrrolidone (PVP), which creates a functionalized coating on the outside of the particles. The nanorods have been shown to have antibacterial properties against both Gram-positive and Gram-negative bacteria, as well as anticancer properties when tested with human melanoma cells.



traducir


 

DEOXYRIBONUCLEIC ACID NANOPARTICLES FOR DELIVERING PROTEINS AND PROTEIN-CONTAINING COMPOUNDS AND METHODS OF MANUFACTURING DEOXYRIBONUCLEIC ACID NANOPARTICLES

NºPublicación: US2019307705A1 10/10/2019

Solicitante:
CHANDRAN PREETHI [US]
HOWARD UNIV [US]

Resumen de: US2019307705A1

Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.



traducir


 

MIR-17~92 AS THERAPEUTIC OR DIAGNOSTIC TARGET OF MOTOR NEURON (MN) DEGENERATION DISEASES

NºPublicación: WO2019195304A1 10/10/2019

Solicitante:
ACAD SINICA
SHIH MING CHE [US]

Resumen de: WO2019195304A1

The present disclosure relates to mir-17~92 as a candidate therapeutic or diagnostic target of motor neuron (MN) degeneration diseases. Expression of mir-17~92 is sustained throughout adulthood in spinal MNs and specifically decreases before the onset of MN loss in SOD1 G93A mice. Accordingly, mir-17~92 can be used as a candidate therapeutic target for ALS.



traducir


 

MULTI-COMPONENT NANOCHAINS

NºPublicación: US2019307687A1 10/10/2019

Solicitante:
UNIV CASE WESTERN RESERVE [US]

Resumen de: US2019307687A1

A multi-component nanochain for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. At least one nanoparticle of the nanochain has an asymmetric surface chemistry defined by asymmetrically disposed first linkers and second linkers. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.



traducir


 

TARGETED DRUG DELIVERY AND THERAPEUTIC METHODS USING APO-E MODIFIED LIPID NANOPARTICLES

NºPublicación: WO2019195377A1 10/10/2019

Solicitante:
ERIOCHEM USA LLC [US]

Resumen de: WO2019195377A1

Methods for targeted delivery of therapeutic agents to a target cell or tissue with lipid nanoparticles comprising ApoE3. In embodiments, the invention specifically relates to targeted delivery of anticancer drugs, antibiotics, antifungal drugs, and diagnostic contrast agents, and associated treatment and diagnostic methods. In embodiments, diseases/conditions treated include those associated with over-expression of LDL receptors.



traducir


 

TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS

NºPublicación: AU2019232934A1 10/10/2019

Solicitante:
SELECTA BIOSCIENCES INC

Resumen de: AU2019232934A1

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins. See Fig. 6. WO 2012/149255 PCT/US2012/035366 100000- Un u u~1000 - -0 100- 1- 0 U' z Fig. 6 530 * + 20 ,+-10 L/) r z Fig. 7



traducir


 

TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY

NºPublicación: AU2019232938A1 10/10/2019

Solicitante:
SELECTA BIOSCIENCES INC

Resumen de: AU2019232938A1

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class Il-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. See Fig. 8.



traducir


 

TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES

NºPublicación: AU2019232931A1 10/10/2019

Solicitante:
SELECTA BIOSCIENCES INC

Resumen de: AU2019232931A1

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.



traducir


 

TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS

NºPublicación: AU2019232928A1 10/10/2019

Solicitante:
SELECTA BIOSCIENCES INC

Resumen de: AU2019232928A1

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II restricted epitopes that can generate tolerogenic immune responses (e.g., antigen- specific T effector cell deletion). See Fig. 5. WO 2012/149393 PCT/US2012/035555 5- 1.5 0- 0.0-- UlA = lA ~ ~> ~ ~ > D~0 LA D 0 Ln z z Fig. 4 5- 2.5 u U 4-~ 2.0 co T 0 3- C) 1.5 0) 0) 1.0 > . 0.5 E Q ~~0.0111 1 0i Ul 0 LA = C CL0 LA - LA z z Fig. 5



traducir


 

PEPTIDE NANOFIBERS

NºPublicación: WO2019193327A1 10/10/2019

Solicitante:
UNIV OF PORTSMOUTH HIGHER EDUCATION CORPORATION [GB]

Resumen de: WO2019193327A1

a nanofiber comprising a peptide GPCR modulator conjugated to a lipophilic moiety where in the peptide-lipophilic moiety conjugate comprises a poly(proline) type II helix structure.



traducir


 

METHOD FOR ENHANCED DELIVERY OF GENE BASED THERAPY AND VACCINATION USING ELECTROPORATION

NºPublicación: US2019307704A1 10/10/2019

Solicitante:
ZHANG YUAN [US]

Resumen de: US2019307704A1

Embodiments of the present invention are generally related to a method of enhancing the transfection efficiency and immunological/pharmacological/therapeutic responses of concurrent gene-based vaccinations or therapies delivered by a wide range of non-viral particles, viral vectors or viral-biomaterials hybrid particles. In particular, embodiments of the present invention are directed to a method of electroporation which enhances the transfection efficiency of RNA replicon loaded lipid-based nanoparticles in-vivo as well as greatly improves immunogen-specific immune responses of such RNA-based vaccinations. This invention also applies to other gene-based vaccination and therapy using non-viral particles, viral based vectors or viral-biomaterials hybrid particles, in conjunction with the said electroporation regimen.



traducir


 

MULTI-FUNCTIONAL NANOPARTICLES FOR VACCINATION

NºPublicación: US2019307703A1 10/10/2019

Solicitante:
ZHANG YUAN [US]

Resumen de: US2019307703A1

The present invention generally relates to a dynamic nanoparticle used for vaccination. Specifically, the claimed product comprises of an adaptive nanoparticle wherein both the outer surface and the inner core are customizable for targeted application.



traducir


 

SELF-ASSEMBLED GELS FOR CONTROLLED DELIVERY OF BIOLOGICS AND METHODS OF MAKING THEREOF

NºPublicación: US2019307885A1 10/10/2019

Solicitante:
ALIVIO THERAPEUTICS INC [US]

Resumen de: US2019307885A1

Gels are formed based on generally recognized as safe (GRAS) low molecular weight amphiphilic molecules in a self-assembly process. Therapeutic or prophylactic agents, such as biological macromolecules, are loaded without exposure to temperatures and/or organic solvents which can degrade or destroy the biologic agents and/or their activity. The resulting self-assembled gel composition contains microstructures having pores and aqueous domains at their interior, rendering them permeable to hydrophilic and hydrophobic molecules. This permeability allows sequestration of the biological macromolecules. Once sequestered, the electrostatic, hydrophobic-hydrophobic etc. interactions between the biological macromolecules and the amphiphilic gelators keep the labile payload encapsulated with high stability until the microstructures are degraded.



traducir


 

ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES AND METHODS FOR USE THEREOF

NºPublicación: US2019307894A1 10/10/2019

Solicitante:
UNIV NAT CHENG KUNG [TW]

Resumen de: US2019307894A1

A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.



traducir


 

LIPID NANOPARTICLES FOR TRANSFECTION AND RELATED METHODS

NºPublicación: US2019307689A1 10/10/2019

Solicitante:
UNIV BRITISH COLUMBIA [CA]

Resumen de: US2019307689A1

Transfection reagent composition, lipid nanoparticles prepared from the transfection reagent composition, kits that include the transfection reagent composition, and methods for making and using lipid nanoparticles prepared from the transfection reagent composition. Lipids when dispersed in aqueous media readily form liposomes, such as unilamellar vesicles and multilamellar vesicles. Liposomes have been used successfully to encapsulate and deliver a wide range of chemicals including nucleic acids, proteins and, small molecule drugs, to cells.



traducir


 

NANOCAPSULE WITH LIQUID OIL CORE, ITS PREPARATION METHOD AND APPLICATION

NºPublicación: WO2019194692A1 10/10/2019

Solicitante:
UNIV JAGIELLONSKI [PL]

Resumen de: WO2019194692A1

The use of nanocapsules with an oil core in anti-cancer therapy has been disclosed, particularly in the treatment of mammary gland tumor or melanoma.



traducir


 

COMPLEXES OF CELECOXIB AND ITS SALTS AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

NºPublicación: US2019307777A1 10/10/2019

Solicitante:
DRUGGABILITY TECH IP HOLDCO LTD [MT]

Resumen de: US2019307777A1

Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment.



traducir


 

POLYPLEX DELIVERY SYSTEM FOR PROTEINS, NUCLEIC ACIDS AND PROTEIN/NUCLEIC ACID COMPLEXES

NºPublicación: US2019307888A1 10/10/2019

Solicitante:
WISCONSIN ALUMNI RES FOUND [US]

Resumen de: US2019307888A1

Provided herein are nanoplexes comprising a payload selected from a protein and/or a polynucleic acid; and a plurality of copolymers comprising a first copolymer that is poly(N,N′-bis(acryloyl)cystamine-poly(aminoalkyl)) (PBAP), a second copolymer that is poly(C2-3 akylene glycol)-PBAP-poly(C2-3 akylene glycol), and a third copolymer that is TG-poly(C2-3 akylene glycol)-PBAP-poly(C2-3 akylene glycol)-TG wherein TG at each occurrence is independently a targeting ligand, a cell penetrating peptide, an imaging agent or a capping group, provided that a plurality of TG groups is a targeting ligand; wherein the payload is non-covalently complexed to one or more of the copolymers, one or more of the first, second, and/or third copolymers comprises an endosomal escape group having a pKa of about 4.5 to about 6.5, and optionally one or more of the first, second, and/or third copolymers comprises a host and a guest non-covalent crosslinker.



traducir


 

NOVEL STEM CELL CARRIER AND METHOD FOR PREPARING THE SAME

NºPublicación: US2019307688A1 10/10/2019

Solicitante:
POSTECH ACAD IND FOUND [KR]

Resumen de: US2019307688A1

The present disclosure relates to a novel stem cell carrier and a method for producing the same and provides a method for producing a stem cell carrier including a step of contacting stem cells with a coacervate formed by mixing an anionic polymer with a mussel adhesive protein or a mutant thereof. The present disclosure relates to a novel stem cell therapeutic agent platform of delivering cells in a encapsulated state by forming an adhesive cell carrier using crosslinked coacervate. The cell carrier of the present disclosure can maintain the ability to differentiate stem cells as well as biocompatibility and can survive without losing cell adhesion even under oxygen-deficient conditions. In addition, the cell carrier of the present disclosure has an excellent regenerative effect by applying such to biological tissues in which vascular regeneration is not easy, by inducing a metabolic reaction triggered by the hypoxic environment, in particular, neovascularization.



traducir


 

NANOVESICLES WITH PORPHYRIN-LIPID CONJUGATE CORE

Nº publicación: US2019307893A1 10/10/2019

Solicitante:
UNIV HEALTH NETWORK [CA]

Resumen de: US2019307893A1

The application relates to liposomal nanovesicles comprising porphyrin-lipid conjugates within the liposomal lipid bilayer. Said porphyrin-lipid conjugate comprise porphyrins that are modified with a —CH(R1)—O—R2 group and that chelate a metal ion. Such modifications of the porphyrin allow for ordered assembly in the lipid bilayer of the nanovesicles while resulting in a bathochromic shift in the wavelength of light absorbed by the porphyrin chromophore. These nanovesicles can be used for photothermal therapy, photodynamic therapy, photoacoustic imaging and fluorescence imaging. The application also teaches methods for preparing the porphyrin-lipid conjugates and the nanovesicles.


traducir



 

Página1 de 8 nextPage Mostrar por página

Volver